EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Open accessThe DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Abstract
OBJECTIVE To present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on screening, diagnosis, and local treatment of clinically localised prostate cancer (PCa). EVIDENCE ACQUISITION The panel performed a literature review of new data, covering the time frame between 2016 and 2020. The guidelines were updated and a strength rating for each recommendation was added based on a systematic review of the evidence. EVIDENCE SYNTHESIS A risk-adapted strategy for identifying men who may develop PCa is advised, generally commencing at 50 yr of age and based on individualised life expectancy. Risk-adapted screening should be offered to men at increased risk from the age of 45 yr and to breast cancer susceptibility gene (BRCA) mutation carriers, who have been confirmed to be at risk of early and aggressive disease (mainly BRAC2), from around 40 yr of age. The use of multiparametric magnetic resonance imaging in order to avoid unnecessary biopsies is recommended. When a biopsy is performed, a combination of targeted and systematic biopsies must be offered. There is currently no place for the routine use of tissue-based biomarkers. Whilst prostate-specific membrane antigen positron emission tomography computed tomography is the most sensitive staging procedure, the lack of outcome benefit remains a major limitation. Active surveillance (AS) should always be discussed with low-risk patients, as well as with selected intermediate-risk patients with favourable International Society of Urological Pathology (ISUP) 2 lesions. Local therapies are addressed, as well as the AS journey and the management of persistent prostate-specific antigen after surgery. A strong recommendation to consider moderate hypofractionation in intermediate-risk patients is provided. Patients with cN1 PCa should be offered a local treatment combined with long-term hormonal treatment. CONCLUSIONS The evidence in the field of diagnosis, staging, and treatment of localised PCa is evolving rapidly. The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on PCa summarise the most recent findings and advice for their use in clinical practice. These PCa guidelines reflect the multidisciplinary nature of PCa management. PATIENT SUMMARY Updated prostate cancer guidelines are presented, addressing screening, diagnosis, and local treatment with curative intent. These guidelines rely on the available scientific evidence, and new insights will need to be considered and included on a regular basis. In some cases, the supporting evidence for new treatment options is not yet strong enough to provide a recommendation, which is why continuous updating is important. Patients must be fully informed of all relevant options and, together with their treating physicians, decide on the most optimal management for them.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742 · cited 1×
“Country-specific life tables are available; however, survival must be individualised [78] based, for example, on gait speed [79] or using tools such as the Cumulative Illness Score Rating — Geriatrics (CISR-G) [80], the Charlson Comorbidity Index (CCI) [81], or the clinical frailty score [82].”
MethodGait speed and survival in older adults.
Studenski, S. (2011) · JAMA · doi:10.1001/jama.2010.1923 · Cited by 4,558 · cited 1×
“Country-specific life tables are available; however, survival must be individualised [78] based, for example, on gait speed [79] or using tools such as the Cumulative Illness Score Rating — Geriatrics (CISR-G) [80], the Charlson Comorbidity Index (CCI) [81], or the clinical frailty score [82].”
MethodA standard procedure for creating a frailty index
Searle, S. D., Mitnitski, A., Gahbauer, E. A., Gill, T. M., & Rockwood, K. (2008) · BMC Geriatrics · doi:10.1186/1471-2318-8-24 · Cited by 3,568
Epstein, J. I., Egevad, L., Amin, M. B., Delahunt, B., Srigley, J. R., & Humphrey, P. A. (2016) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000530 · Cited by 3,236
Mottet, N., Bellmunt, J., Bolla, M., Briers, E., Cumberbatch, M. G., De Santis, M., Fossati, N., Gross, T., Henry, A. M., Joniau, S., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.08.003 · Cited by 3,227
Self-citationMRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis
Kasivisvanathan, V., Rannikko, A. S., Borghi, M., Panebianco, V., Mynderse, L. A., Vaarala, M. H., Briganti, A., Budäus, L., Hellawell, G., Hindley, R. G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801993 · Cited by 3,091
PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2
Weinreb, J. C., Barentsz, J. O., Choyke, P. L., Cornud, F., Haider, M. A., Macura, K. J., Margolis, D., Schnall, M. D., Shtern, F., Tempany, C. M., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.08.052 · Cited by 2,951
Epstein, J. I., Allsbrook, W. C., Amin, M. B., & Egevad, L. L. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000173646.99337.b1 · Cited by 2,763
Hofman, M. S., Lawrentschuk, N., Francis, R. J., Tang, C., Vela, I., Thomas, P., Rutherford, N., Martin, J. M., Frydenberg, M., Shakher, R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30314-7 · Cited by 2,040
Going from evidence to recommendations
Guyatt, G. H., Oxman, A. D., Kunz, R., Falck-Ytter, Y., Vist, G. E., Liberati, A., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39493.646875.ae · Cited by 1,810
Radical Prostatectomy versus Observation for Localized Prostate Cancer
Wilt, T. J., Brawer, M. K., Jones, K. M., Barry, M. J., Aronson, W. J., Fox, S., Gingrich, J. R., Wei, J. T., Gilhooly, P., Grob, B. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113162 · Cited by 1,770
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Zappa, M., Nelen, V., Kwiatkowski, M., Lujan, M., Määttänen, L., Lilja, H., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60525-0 · Cited by 1,566
Self-citationThe benefits and harms of breast cancer screening: an independent review
(2012) · The Lancet · doi:10.1016/s0140-6736(12)61611-0 · Cited by 1,492
Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Grossman, D. C., Curry, S. J., Owens, D. K., Bibbins-Domingo, K., Caughey, A. B., Davidson, K. W., Doubeni, C. A., Ebell, M., Epling, J. W., et al. (2018) · JAMA · doi:10.1001/jama.2018.3710 · Cited by 1,436
The Mini-Cog as a screen for dementia: validation in a population-based sample
Borson, S., Scanlan, J. M., Chen, P., & Ganguli, M. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2003.51465.x · Cited by 1,348 · cited 1×
“The International SIOG PCa Working Group recommends that treatment for senior adults should be based on a systematic evaluation of health status using the G8 screening tool [36] as well as the Mini-COG [83].”
MethodDearnaley, D., Syndikus, I., Mossop, H., Khoo, V., Birtle, A., Bloomfield, D., Graham, J., Kirkbride, P., Logue, J., Malik, Z., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30102-4 · Cited by 1,339
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
Donovan, J. L., Hamdy, F. C., Lane, J. A., Mason, M., Metcalfe, C., Walsh, E., Blazeby, J. M., Peters, T. J., Holding, P., Bonnington, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606221 · Cited by 1,338
Self-citationFicarra, V., Novara, G., Rosen, R. C., Artibani, W., Carroll, P. R., Costello, A., Menon, M., Montorsi, F., Patel, V. R., Stolzenburg, J.-U., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.05.045 · Cited by 1,300
Self-citationThompson, I. M., Tangen, C. M., Paradelo, J., Lucia, M. S., Miller, G., Troyer, D., Messing, E., Forman, J., Chin, J., Swanson, G., et al. (2009) · Journal of Urology · doi:10.1016/j.juro.2008.11.032 · Cited by 1,227
Ilic, D., Neuberger, M. M., Djulbegovic, M., & Dahm, P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004720.pub3 · Cited by 1,150
Rouvière, O., Puech, P., Renard-Penna, R., Claudon, M., Roy, C., Mège-Lechevallier, F., Decaussin-Petrucci, M., Dubreuil-Chambardel, M., Magaud, L., Remontet, L., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30569-2 · Cited by 1,095
Self-citationCancer Screening in Elderly Patients: A Framework for Individualized Decision Making
Walter, L. C., & Covinsky, K. E. (2001) · JAMA · doi:10.1001/jama.285.21.2750 · Cited by 1,003 · cited 1×
“Country-specific life tables are available; however, survival must be individualised [78] based, for example, on gait speed [79] or using tools such as the Cumulative Illness Score Rating — Geriatrics (CISR-G) [80], the Charlson Comorbidity Index (CCI) [81], or the clinical frailty score [82].”
MethodRadical Prostatectomy or Watchful Waiting in Early Prostate Cancer
Bill-Axelson, A., Holmberg, L., Garmo, H., Rider, J. R., Taari, K., Busch, C., Nordling, S., Häggman, M., Andersson, S.-O., Spångberg, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311593 · Cited by 981
Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer
Resnick, M. J., Koyama, T., Fan, K.-H., Albertsen, P. C., Goodman, M., Hamilton, A. S., Hoffman, R. M., Potosky, A. L., Stanford, J. L., Stroup, A. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209978 · Cited by 979
Duration of Androgen Suppression in the Treatment of Prostate Cancer
Bolla, M., de Reijke, T. M., Van Tienhoven, G., Van den Bergh, A. C. M., Oddens, J., Poortmans, P. M. P., Gez, E., Kil, P., Akdas, A., Soete, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810095 · Cited by 970
Perera, M., Papa, N., Roberts, M., Williams, M., Udovicich, C., Vela, I., Christidis, D., Bolton, D., Hofman, M. S., Lawrentschuk, N., et al. (2020) · European Urology · doi:10.1016/j.eururo.2019.01.049 · Cited by 958
Hövels, A. M., Heesakkers, R. A. M., Adang, E. M., Jager, G. J., Strum, S., Hoogeveen, Y. L., Severens, J. L., & Barentsz, J. O. (2008) · Clinical Radiology · doi:10.1016/j.crad.2007.05.022 · Cited by 954
Bolla, M., Van Tienhoven, G., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Billiet, I., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70223-0 · Cited by 946
Self-citationPilepich, M. V., Winter, K., Lawton, C. A., Krisch, R. E., Wolkov, H. B., Movsas, B., Hug, E. B., Asbell, S. O., & Grignon, D. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.08.047 · Cited by 913
Messing, E. M., Manola, J., Yao, J., Kiernan, M., Crawford, D., Wilding, G., di'SantAgnese, P. A., & Trump, D. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70700-8 · Cited by 893
Widmark, A., Gunnlaugsson, A., Beckman, L., Thellenberg-Karlsson, C., Hoyer, M., Lagerlund, M., Kindblom, J., Ginman, C., Johansson, B., Björnlinger, K., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31131-6 · Cited by 876
Bolla, M., van Poppel, H., Tombal, B., Vekemans, K., Da Pozzo, L., de Reijke, T. M., Verbaeys, A., Bosset, J.-F., van Velthoven, R., Colombel, M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61253-7 · Cited by 867
Variations in Morbidity after Radical Prostatectomy
Begg, C. B., Riedel, E. R., Bach, P. B., Kattan, M. W., Schrag, D., Warren, J. L., & Scardino, P. T. (2002) · New England Journal of Medicine · doi:10.1056/nejmsa011788 · Cited by 840
Briganti, A., Larcher, A., Abdollah, F., Capitanio, U., Gallina, A., Suardi, N., Bianchi, M., Sun, M., Freschi, M., Salonia, A., et al. (2012) · European Urology · doi:10.1016/j.eururo.2011.10.044 · Cited by 786
van der Leest, M., Cornel, E., Israël, B., Hendriks, R., Padhani, A. R., Hoogenboom, M., Zamecnik, P., Bakker, D., Setiasti, A. Y., Veltman, J., et al. (2019) · European Urology · doi:10.1016/j.eururo.2018.11.023 · Cited by 777
Morris, W. J., Tyldesley, S. K., Rodda, S. L., Halperin, R. M., Pai, H. H., McKenzie, M. R., Duncan, G. G., Morton, G., Hamm, J., & Murray, N. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.11.026 · Cited by 753
Zietman, A. L., Bae, K., Slater, J. D., Shipley, W. U., Efstathiou, J. A., Coen, J. J., Bush, D. A., Lunt, M., Spiegel, D. Y., Skowronski, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8475 · Cited by 735
Zelefsky, M. J., Levin, E. J., Hunt, M., Yamada, Y., Shippy, A. M., Jackson, A., & Amols, H. I. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.11.044 · Cited by 735
Catton, C. N., Lukka, H., Gu, C.-S., Martin, J. M., Supiot, S., Chung, P. W. M., Bauman, G. S., Bahary, J.-P., Ahmed, S., Cheung, P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.7397 · Cited by 713
van Leenders, G. J. L. H., van der Kwast, T. H., Grignon, D. J., Evans, A. J., Kristiansen, G., Kweldam, C. F., Litjens, G., McKenney, J. K., Melamed, J., Mottet, N., et al. (2020) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001497 · Cited by 713
Self-citationA 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer
Hugosson, J., Roobol, M. J., Månsson, M., Tammela, T. L. J., Zappa, M., Nelen, V., Kwiatkowski, M., Lujan, M., Carlsson, S. V., Talala, K. M., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.02.009 · Cited by 698
Self-citationRadiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer
Jones, C. U., Hunt, D., McGowan, D. G., Amin, M. B., Chetner, M. P., Bruner, D. W., Leibenhaut, M. H., Husain, S. M., Rotman, M., Souhami, L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012348 · Cited by 696
de Rooij, M., Hamoen, E. H. J., Witjes, J. A., Barentsz, J. O., & Rovers, M. M. (2016) · European Urology · doi:10.1016/j.eururo.2015.07.029 · Cited by 669
Drost, F.-J. H., Osses, D. F., Nieboer, D., Steyerberg, E. W., Bangma, C. H., Roobol, M. J., & Schoots, I. G. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012663.pub2 · Cited by 640
Self-citationLee, W. R., Dignam, J. J., Amin, M. B., Bruner, D. W., Low, D., Swanson, G. P., Shah, A. B., D’Souza, D. P., Michalski, J. M., Dayes, I. S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.0448 · Cited by 625
Follow-up of Prostatectomy versus Observation for Early Prostate Cancer
Wilt, T. J., Jones, K. M., Barry, M. J., Andriole, G. L., Culkin, D., Wheeler, T., Aronson, W. J., & Brawer, M. K. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615869 · Cited by 623
Brand, D. H., Tree, A. C., Ostler, P. J., van der Voet, H., Loblaw, A., Chu, W., Ford, D., Tolan, S. P., Jain, S., Martin, A. S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30569-8 · Cited by 572
Fenton, J. J., Weyrich, M. S., Durbin, S., Liu, Y., Bang, H., & Melnikow, J. (2018) · JAMA · doi:10.1001/jama.2018.3712 · Cited by 555
Incrocci, L., Wortel, R. C., Alemayehu, W. G., Aluwini, S., Schimmel, E. C., Krol, A. D. G., van der Toorn, P.-P., de Jager, H., Heemsbergen, W. D., Heijmen, B. J. M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30070-5 · Cited by 525
Arnold, M., Karim-Kos, H. E., Coebergh, J. W., Byrnes, G., Antilla, A., Ferlay, J., Renehan, A. G., Forman, D., & Soerjomataram, I. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2013.09.002 · Cited by 513
Haglind, E., Carlsson, S., Stranne, J., Wallerstedt, A., Wilderäng, U., Thorsteinsdottir, T., Lagerkvist, M., Damber, J.-E., Bjartell, A., Hugosson, J., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.02.029 · Cited by 497
Lawton, C. A., DeSilvio, M., Roach, M., Uhl, V., Kirsch, R., Seider, M., Rotman, M., Jones, C., Asbell, S., Valicenti, R., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.04.003 · Cited by 480
Coughlin, G. D., Yaxley, J. W., Chambers, S. K., Occhipinti, S., Samaratunga, H., Zajdlewicz, L., Teloken, P., Dunglison, N., Williams, S., Lavin, M. F., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30357-7 · Cited by 465
Grimm, P., Billiet, I., Bostwick, D., Dicker, A. P., Frank, S., Immerzeel, J., Keyes, M., Kupelian, P., Lee, W. R., Machtens, S., et al. (2012) · BJU International · doi:10.1111/j.1464-410x.2011.10827.x · Cited by 462
70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial
Beckendorf, V., Guerif, S., Le Prisé, E., Cosset, J.-M., Bougnoux, A., Chauvet, B., Salem, N., Chapet, O., Bourdain, S., Bachaud, J.-M., et al. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.03.049 · Cited by 452
Wiegel, T., Bartkowiak, D., Bottke, D., Bronner, C., Steiner, U., Siegmann, A., Golz, R., Störkel, S., Willich, N., Semjonow, A., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.03.011 · Cited by 440
Self-citationMartin, R. M., Donovan, J. L., Turner, E. L., Metcalfe, C., Young, G. J., Walsh, E. I., Lane, J. A., Noble, S., Oliver, S. E., Evans, S., et al. (2018) · JAMA · doi:10.1001/jama.2018.0154 · Cited by 415
Jackson, W., Silva, J., Hartman, H. E., Dess, R. T., Kishan, A. U., Beeler, W. H., Gharzai, L. A., Jaworski, E. M., Mehra, R., Hearn, J. W. D., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.03.051 · Cited by 399
Castro, E., Goh, C., Leongamornlert, D., Saunders, E., Tymrakiewicz, M., Dadaev, T., Govindasami, K., Guy, M., Ellis, S., Frost, D., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.10.022 · Cited by 368
Roach, P. J., Francis, R., Emmett, L., Hsiao, E., Kneebone, A., Hruby, G., Eade, T., Nguyen, Q. A., Thompson, B. D., Cusick, T., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.197160 · Cited by 367
Nicolosi, P., Ledet, E., Yang, S., Michalski, S., Freschi, B., O’Leary, E., Esplin, E. D., Nussbaum, R. L., & Sartor, O. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.6760 · Cited by 365
Shen, G., Deng, H., Hu, S., & Jia, Z. (2014) · Skeletal Radiology · doi:10.1007/s00256-014-1903-9 · Cited by 363
Michalski, J. M., Moughan, J., Purdy, J., Bosch, W., Bruner, D. W., Bahary, J.-P., Lau, H., Duclos, M., Parliament, M., Morton, G., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0039 · Cited by 356
Walz, J., Epstein, J. I., Ganzer, R., Graefen, M., Guazzoni, G., Kaouk, J., Menon, M., Mottrie, A., Myers, R. P., Patel, V., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.01.026 · Cited by 330
Gandaglia, G., Ploussard, G., Valerio, M., Mattei, A., Fiori, C., Fossati, N., Stabile, A., Beauval, J.-B., Malavaud, B., Roumiguié, M., et al. (2019) · European Urology · doi:10.1016/j.eururo.2018.10.012 · Cited by 322
Self-citationImpact of Comorbidity on Survival Among Men With Localized Prostate Cancer
Albertsen, P. C., Moore, D. F., Shih, W., Lin, Y., Li, H., & Lu-Yao, G. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.2330 · Cited by 312
Impact of Adjuvant Radiotherapy on Survival of Patients With Node-Positive Prostate Cancer
Abdollah, F., Karnes, R. J., Suardi, N. R., Cozzarini, C., Gandaglia, G., Fossati, N., Vizziello, D., Sun, M., Karakiewicz, P. I., Menon, M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.7893 · Cited by 310
Self-citationRisk factors for the onset of prostatic cancer: age, location, and behavioral correlates
Leitzmann, M., & Rohrmann, S. (2012) · Clinical Epidemiology · doi:10.2147/clep.s16747 · Cited by 304
Lecouvet, F. E., El Mouedden, J., Collette, L., Coche, E., Danse, E., Jamar, F., Machiels, J.-P., Vande Berg, B., Omoumi, P., & Tombal, B. (2012) · European Urology · doi:10.1016/j.eururo.2012.02.020 · Cited by 303
New and Established Technology in Focal Ablation of the Prostate: A Systematic Review
Valerio, M., Cerantola, Y., Eggener, S. E., Lepor, H., Polascik, T. J., Villers, A., & Emberton, M. (2017) · European Urology · doi:10.1016/j.eururo.2016.08.044 · Cited by 300
Hoffman, K. E., Penson, D. F., Zhao, Z., Huang, L.-C., Conwill, R., Laviana, A. A., Joyce, D. D., Luckenbaugh, A. N., Goodman, M., Hamilton, A. S., et al. (2020) · JAMA · doi:10.1001/jama.2019.20675 · Cited by 298
Budäus, L., Bolla, M., Bossi, A., Cozzarini, C., Crook, J., Widmark, A., & Wiegel, T. (2012) · European Urology · doi:10.1016/j.eururo.2011.09.027 · Cited by 288
Self-citationVickers, A. J., Ulmert, D., Sjoberg, D. D., Bennette, C. J., Bjork, T., Gerdtsson, A., Manjer, J., Nilsson, P. M., Dahlin, A., Bjartell, A., et al. (2013) · BMJ · doi:10.1136/bmj.f2023 · Cited by 282
Mason, M. D., Parulekar, W. R., Sydes, M. R., Brundage, M., Kirkbride, P., Gospodarowicz, M. K., Cowan, R. A., Kostashuk, E. C., Anderson, J., Swanson, G. P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.7510 · Cited by 275
Self-citationXiang, J., Yan, H., Li, J., Wang, X., Chen, H., & Zheng, X. (2019) · World Journal of Surgical Oncology · doi:10.1186/s12957-019-1573-0 · Cited by 272
Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis
Wallis, C. J. D., Mahar, A. L., Choo, R., Herschorn, S., Kodama, R. T., Shah, P. S., Danjoux, C., Narod, S. A., & Nam, R. K. (2016) · BMJ · doi:10.1136/bmj.i851 · Cited by 271
Naji, L., Randhawa, H., Sohani, Z., Dennis, B., Lautenbach, D., Kavanagh, O., Bawor, M., Banfield, L., & Profetto, J. (2018) · The Annals of Family Medicine · doi:10.1370/afm.2205 · Cited by 271
Ramsay, C., Pickard, R., Robertson, C., Close, A., Vale, L., Armstrong, N., Barocas, D., Eden, C., Fraser, C., Gurung, T., et al. (2012) · Health Technology Assessment · doi:10.3310/hta16410 · Cited by 260
Self-citationNeo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer
Kumar, S., Shelley, M., Harrison, C., Coles, B., Wilt, T. J., & Mason, M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006019.pub2 · Cited by 257
Self-citationKuban, D. A., Levy, L. B., Cheung, M. R., Lee, A. K., Choi, S., Frank, S., & Pollack, A. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.01.006 · Cited by 257
Lardas, M., Liew, M., van den Bergh, R. C., De Santis, M., Bellmunt, J., Van den Broeck, T., Cornford, P., Cumberbatch, M. G., Fossati, N., Gross, T., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.06.035 · Cited by 256
Self-citationCarr, A. J., Cooper, C. D., Campbell, M. K., Rees, J. L., Moser, J., Beard, D. J., Fitzpatrick, R., Gray, A., Dawson, J., Murphy, J., et al. (2015) · Health Technology Assessment · doi:10.3310/hta19800 · Cited by 248
Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study
Nyberg, T., Frost, D., Barrowdale, D., Evans, D. G., Bancroft, E., Adlard, J., Ahmed, M., Barwell, J., Brady, A. F., Brewer, C., et al. (2020) · European Urology · doi:10.1016/j.eururo.2019.08.025 · Cited by 248
Page, E. C., Bancroft, E. K., Brook, M. N., Assel, M., Hassan Al Battat, M., Thomas, S., Taylor, N., Chamberlain, A., Pope, J., Raghallaigh, H. N., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.08.019 · Cited by 247
Lam, T. B. L., MacLennan, S., Willemse, P.-P. M., Mason, M. D., Plass, K., Shepherd, R., Baanders, R., Bangma, C. H., Bjartell, A., Bossi, A., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.09.020 · Cited by 243
Self-citationFizazi, K., Faivre, L., Lesaunier, F., Delva, R., Gravis, G., Rolland, F., Priou, F., Ferrero, J.-M., Houede, N., Mourey, L., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00011-x · Cited by 239
Boyle, H. J., Alibhai, S., Decoster, L., Efstathiou, E., Fizazi, K., Mottet, N., Oudard, S., Payne, H., Prentice, M., Puts, M., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.031 · Cited by 236
Self-citationKweldam, C. F., Kümmerlin, I. P., Nieboer, D., Verhoef, E. I., Steyerberg, E. W., van der Kwast, T. H., Roobol, M. J., & van Leenders, G. J. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.49 · Cited by 235
Self-citationMolecular Biomarkers in Localized Prostate Cancer: ASCO Guideline
Eggener, S. E., Rumble, R. B., Armstrong, A. J., Morgan, T. M., Crispino, T., Cornford, P., van der Kwast, T., Grignon, D. J., Rai, A. J., Agarwal, N., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02768 · Cited by 223
Self-citationKelly, S. P., Anderson, W. F., Rosenberg, P. S., & Cook, M. B. (2018) · European Urology Focus · doi:10.1016/j.euf.2017.10.014 · Cited by 217
Godtman, R. A., Holmberg, E. C., Lilja, H. G., Stranne, J., & Hugosson, J. (2014) · European Urology · doi:10.1016/j.eururo.2014.12.006 · Cited by 212
Effect of metabolic syndrome and its components on prostate cancer risk: Meta-analysis
Esposito, K., Chiodini, P., Capuano, A., Bellastella, G., Maiorino, M. I., Parretta, E., Lenzi, A., & Giugliano, D. (2013) · Journal of Endocrinological Investigation · doi:10.1007/bf03346748 · Cited by 209
Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography
Tan, D. S. W., Mok, T. S. K., & Rebbeck, T. R. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.0096 · Cited by 202
Yossepowitch, O., Eggener, S. E., Serio, A. M., Carver, B. S., Bianco, F. J., Scardino, P. T., & Eastham, J. A. (2008) · European Urology · doi:10.1016/j.eururo.2007.10.008 · Cited by 193
James, N. D., Spears, M. R., Clarke, N. W., Dearnaley, D. P., Mason, M. D., Parker, C. C., Ritchie, A. W. S., Russell, J. M., Schiavone, F., Attard, G., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4350 · Cited by 188
Self-citationDo prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis
Louie, K. S., Seigneurin, A., Cathcart, P., & Sasieni, P. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu525 · Cited by 183
Meta-analysis of 11C-choline and 18F-choline PET/CT for management of patients with prostate cancer
von Eyben, F. E., & Kairemo, K. (2013) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000040 · Cited by 171
Spahn, M., Joniau, S., Gontero, P., Fieuws, S., Marchioro, G., TOMBAL, B. F., Kneitz, B., Hsu, C., Eeckt, K. V. D., Bader, P., et al. (2010) · European Urology · doi:10.1016/j.eururo.2010.03.001 · Cited by 168
Dose-Escalated Irradiation and Overall Survival in Men With Nonmetastatic Prostate Cancer
Kalbasi, A. K., Li, J., Berman, A. T., Swisher-McClure, S. D., Smaldone, M. C., Uzzo, R. G., Small, D. S., Mitra, N., & Bekelman, J. E. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2316 · Cited by 167
Corfield, J., Perera, M., Bolton, D., & Lawrentschuk, N. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2182-1 · Cited by 167
Loeb, S., Bruinsma, S. M., Nicholson, J., Briganti, A., Pickles, T., Kakehi, Y., Carlsson, S. V., & Roobol, M. J. (2015) · European Urology · doi:10.1016/j.eururo.2014.10.010 · Cited by 166
Neal, D. E., Metcalfe, C., Donovan, J., Lane, J. A., Davis, M., Young, G., Dutton, S., Walsh, E. I., Martin, R. M., Peters, T. J., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.10.030 · Cited by 166
Self-citationRosenthal, S. A., Hu, C., Sartor, O. A., Gomella, L. G., Amin, M. B., Purdy, J. A., Michalski, J. M., Garzotto, M. G., Pervez, N., Balogh, A. G., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02158 · Cited by 163
Moris, L., Cumberbatch, M. G. K., den Broeck, T. V., Gandaglia, G., Fossati, N., Kelly, B. D., Pal, R. P., Briers, E., Cornford, P. A., Santis, M. D., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.01.033 · Cited by 160
Self-citationRoberts, M. J., Bennett, H. Y., Harris, P. N. A., Holmes, M., Grummet, J., Naber, K. G., & Wagenlehner, F. R. A. (2016) · Urology · doi:10.1016/j.urology.2016.12.011 · Cited by 149
Self-citationWalz, J. C., Joniau, S., Chun, F. K. ‐., Isbarn, H., Claudio Jeldres, A., Yossepowitch, O., Hsu, C., Klein, E. A., Scardino, P. T., Reuther, A. M., et al. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09594.x · Cited by 142
Ramsay, C. R., Adewuyi, T. E., Gray, J., Hislop, J., Shirley, M., Jayakody, S., MacLennan, G., Fraser, C. M., MacLennan, S. J., Brazzelli, M. G., et al. (2015) · Health Technology Assessment · doi:10.3310/hta19490 · Cited by 141
Self-citationIncrease in Prostate Cancer Distant Metastases at Diagnosis in the United States
Hu, J. C., Nguyen, P. L., Mao, J., Halpern, J. A., Shoag, J. E., Wright, J. D., & Sedrakyan, A. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5465 · Cited by 139
Sentinel Node Procedure in Prostate Cancer: A Systematic Review to Assess Diagnostic Accuracy
Wit, E. M. K., Acar, C., Grivas, N., Yuan, C., Horenblas, S., Liedberg, F., Olmos, R. A. V., van Leeuwen, F. W. B., van den Berg, N. S., Winter, A., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.09.007 · Cited by 131
Self-citationXue, J., Qin, Z., Cai, H., Zhang, C., Li, X., Xu, W., Wang, J., Xu, Z., Yu, B., Xu, T., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15056 · Cited by 130
Preißer, F., Chun, F. K. ‐., Pompe, R. S., Heinze, A., Salomon, G., Graefen, M., Huland, H., & Derya Tilki, A. (2019) · European Urology · doi:10.1016/j.eururo.2019.01.048 · Cited by 128
Prostate cancer risk prediction based on complete prostate cancer family history
Albright, F. S., Stephenson, R. A., Agarwal, N., Teerlink, C. C., Lowrance, W. T., Farnham, J. M., & Cannon‐Albright, L. (2014) · The Prostate · doi:10.1002/pros.22925 · Cited by 127
van Kalmthout, L. W. M., van Melick, H. H. E., Lavalaye, J., Meijer, R. P., Kooistra, A., de Klerk, J. M. H., Braat, A. J. A. T., Kaldeway, H. P., de Bruin, P. C., de Keizer, B., et al. (2019) · The Journal of Urology · doi:10.1097/ju.0000000000000531 · Cited by 127
Haider, A., Zitzmann, M., Doros, G. D., Isbarn, H., Hammerer, P., & Yassin, A. A. (2014) · The Journal of Urology · doi:10.1016/j.juro.2014.06.071 · Cited by 125
High-Dose-Rate Monotherapy for Localized Prostate Cancer: 10-Year Results
Hauswald, H., Kamrava, M. R., Fallon, J. M., Wang, P., Park, S., Van, T., Zaide, L. B., Steinberg, M. L., & Demanes, D. J. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.07.2290 · Cited by 124
Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review
Lamy, P., Allory, Y., Gauchez, A., Asselain, B. J. R., Beuzeboc, P., de Crémoux, P., Fontugne, J., Georges, A., Hennequin, C., Lehmann‐Che, J., et al. (2017) · European Urology Focus · doi:10.1016/j.euf.2017.02.017 · Cited by 119
Self-citationHamid, S., Donaldson, I. A., Hu, Y., Rodell, R., Villarini, B., Bonmati, E., TRANTER, P. R., Punwani, S., Sidhu, H. S., Willis, S., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.08.007 · Cited by 117
Iversen, P., McLeod, D. G., See, W. A., Morris, T., Armstrong, J. M., Wirth, M. P., & on behalf of the Casodex Early Prostate Cancer Trialists’ Group (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09319.x · Cited by 116
Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies
Watts, E. L., Appleby, P. N., Perez-Cornago, A., Bueno-de-Mesquita, H. B., Chan, J. M., Chen, C., Cohn, B. A., Cook, M. B., Flicker, L., Freedman, N. D., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.07.024 · Cited by 115
Fossati, N., Karnes, R. J., Cozzarini, C., Fiorino, C., Gandaglia, G., Joniau, S., Boorjian, S. A., Goldner, G. M., Hinkelbein, W., Haustermans, K. M., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.10.009 · Cited by 113
Self-citationA Systematic Review of Hypofractionation for Primary Management of Prostate Cancer
Koontz, B. F., Bossi, A., Cozzarini, C., Wiegel, T., & D'Amico, A. V. (2014) · European Urology · doi:10.1016/j.eururo.2014.08.009 · Cited by 108
Self-citationSchoots, I. G., Nieboer, D., Giganti, F., Moore, C. M., Bangma, C. H., & Roobol, M. J. (2018) · British Journal of Urology · doi:10.1111/bju.14358 · Cited by 107
Self-citationChou, R., & Croswell, J. M. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-7-201204030-00017 · Cited by 105
Bruinsma, S. M., Roobol, M. J., Carroll, P. R., Klotz, L. H., Pickles, T., Moore, C. M., Gnanapragasam, V. J., Villers, A. A., Rannikko, A. S., Valdagni, R., et al. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.26 · Cited by 103
Wiegel, T., Bartkowiak, D., Bottke, D., Thamm, R., Hinke, A., Stöckle, M., Rübe, C., Semjonow, A., Wirth, M. P., Störkel, S., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.09.039 · Cited by 90
Self-citationScreening for familial and hereditary prostate cancer
Lynch, H. T., Kosoko‐Lasaki, O., Leslie, S., Rendell, M., Shaw, T. G., Snyder, C., D'Amico, A. V., Buxbaum, S. G., Isaacs, W. B., Loeb, S., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29949 · Cited by 90
Trends in the treatment of localized prostate cancer using supplemented cancer registry data
Hamilton, A. S., Albertsen, P. C., Johnson, T. K., Hoffman, R. M., Morrell, D., Deapen, D., & Penson, D. F. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09514.x · Cited by 89
Heck, M. M., Souvatzoglou, M., Retz, M. M., Nawroth, R., Kübler, H. R., Maurer, T., Thalgott, M. K., Gramer, B. M., Weirich, G., Rondak, I., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2634-1 · Cited by 86
Wu, H. M., Xu, T., Wang, X., Yu, Y., Fan, Z.-Y., Li, D.-X., Luo, L., Yang, X.-C., Jiao, W., & Niu, H. (2019) · The World Journal of Men s Health · doi:10.5534/wjmh.180124 · Cited by 85
Spratt, D. E., Dai, D. L., Den, R. B., Troncoso, P., Yousefi, K., Ross, A. E., Schaeffer, E. M., Haddad, Z., Davicioni, E., Mehra, R., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.11.024 · Cited by 77
Schmidt-Hegemann, N.-S., Fendler, W. P., Ilhan, H., Herlemann, A., Büchner, A., Stief, C. G., Eze, C., Rogowski, P., Li, M., Bartenstein, P., et al. (2018) · Radiation Oncology · doi:10.1186/s13014-018-0983-4 · Cited by 75
Ventimiglia, E., Seisen, T., Abdollah, F., et al. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.02.001 · Cited by 59
Ploussard, G., Staerman, F., Pierrevelcin, J., Saad, R., Beauval, J., Morgan Rouprêt, A., Audenet, F., Peyromaure, M., Delongchamps, N. B., Vincendeau, S., et al. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.04.073 · Cited by 55
Ahlgren, G., Flodgren, P., Tammela, T. L. J., Kellokumpu‐Lehtinen, P., Borre, M., Angelsen, A., Iversen, J. R., Sverrisdóttir, Á., Jónsson, E., & Sengeløv, L. (2018) · European Urology · doi:10.1016/j.eururo.2018.01.012 · Cited by 54
Hypofractionated radiotherapy for localized prostate cancer
Höcht, S., Aebersold, D. M., Albrecht, C. F., Böhmer, D., Flentje, M. P., Ganswindt, U., Hölscher, T., Martin, T. J., Sedlmayer, F., Wenz, F. K., et al. (2016) · Strahlentherapie und Onkologie · doi:10.1007/s00066-016-1041-5 · Cited by 51
Self-citationGroome, P. A., Rohland, S. L., Siemens, D. R., Brundage, M., Heaton, J. P. W., & Mackillop, W. J. (2011) · Cancer · doi:10.1002/cncr.25984 · Cited by 49
Dieffenbacher, S., Nyarangi-Dix, J. N., Giganti, F., Bonekamp, D., Kesch, C. V., Wolf, M. B., Schütz, V., Gasch, C., Hatiboglu, G., Hauffe, M., et al. (2019) · European Urology Focus · doi:10.1016/j.euf.2019.03.001 · Cited by 47
Stewart, R. W., Lizama, S., Peairs, K. S., Sateia, H. F., & Choi, Y. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.02.001 · Cited by 30
Eggener, S. E., Large, M. C., Gerber, G. S., Pettus, J. A., Yossepowitch, O., Smith, N. D., KUNDU, S. D., Kunnavakkam, R., Zorn, K. C., & Raman, J. D. (2013) · British Journal of Urology · doi:10.1111/bju.12241 · Cited by 28
Petrelli, F., Vavassori, I., Cabiddu, M., Coinu, A., Ghilardi, M., Borgonovo, K., Lonati, V., & Barni, S. (2016) · Urology · doi:10.1016/j.urology.2016.01.034 · Cited by 28
Vordermark, D., Wulf, J., Markert, K., Baier, K., Kölbl, O., Beckmann, G. K., Bratengeier, K., Noe, M., Schön, G., & Flentje, M. P. (2006) · Acta Oncologica · doi:10.1080/02841860600710913 · Cited by 25
Cited by
Cornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Brunckhorst, O., Darraugh, J., Eberli, D., De Meerleer, G., De Santis, M., Farolfi, A., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.03.027 · Cited by 1,246
Self-citationCornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.046 · Cited by 1,079
Self-citation2022 Update on Prostate Cancer Epidemiology and Risk Factors—A Systematic Review
Bergengren, O., Pekala, K. R., Matsoukas, K., Fainberg, J., Mungovan, S. F., Bratt, O., Bray, F., Brawley, O., Luckenbaugh, A. N., Mucci, L., et al. (2023) · European Urology · doi:10.1016/j.eururo.2023.04.021 · Cited by 848
Wang, L., Lu, B., He, M., Wang, Y., Wang, Z., & Du, L. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.811044 · Cited by 646
Epidemiology and Prevention of Prostate Cancer
Gandaglia, G., Leni, R., Bray, F., Fleshner, N., Freedland, S. J., Kibel, A., Stattin, P., Van Poppel, H., & La Vecchia, C. (2021) · European Urology Oncology · doi:10.1016/j.euo.2021.09.006 · Cited by 611
Self-citation
Metadata
- Authors
- Mottet, N., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., Grivas, N., Grummet, J., Henry, A. M., van der Kwast, T. H., Lam, T. B., Lardas, M., Liew, M., Mason, M. D., Moris, L., Oprea-Lager, D. E., van der Poel, H. G., Rouvière, O., Schoots, I. G., Tilki, D., Wiegel, T., Willemse, P.-P. M., & Cornford, P.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 79
- Issue
- 2
- Pages
- 243-262
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W3097158220
- Cited by
- 2,802
- References
- 141
- FWCI
- 191.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.